Granted Patent
B2
US 12,194,022 · App. 18/095,612 · Granted Jan 14, 2025
Use of amisulpride as an anti-emetic
Inventors:
Julian Clive Gilbert (Duxford, GB); Robert William Gristwood (Duxford, GB); Nicola Cooper (Ashdon, GB); Gabriel Fox (Duxford, GB)
Assignee:
Acacia Pharma Limited
A61K31/40A61K9/0014A61K9/0019A61K9/0031A61K9/0053A61K31/282A61K31/4178A61K31/485A61K31/573A61K33/24A61K33/243A61K45/06A61K47/12
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Claims (12)
1. A method for the prevention of post-operative nausea and vomiting (PONV) in a human in need of such prevention comprising intravenously administering to the human an anti-emetic, wherein the anti-emetic is S-amisulpride at a dose of 2.5 mg.
2. The method according to claim 1 , wherein the subject is also administered an emetogenic agent.
3. The method according to claim 2 , wherein the emetogenic agent is an opiate.
4. The method according to claim 2 , wherein the emetogenic agent is morphine.
5. The method according to claim 1 , wherein the human is also administered an anesthetic.
6. The method according to claim 1 , wherein the S-amisulpride is administered in combination with another anti-emetic drug.
7. The method according to claim 6 , wherein the another anti-emetic drug is a 5HT3 antagonist, an NK1 antagonist, or a steroid.
8. The method of claim 7 , wherein the another anti-emetic is dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant or rolapitant.
9. The method according to claim 7 , wherein the 5HT3 antagonist is ondansetron.
10. The method of claim 1 , wherein the S-amisulpride is administered in the form of a pharmaceutical composition comprising S-amisulpride, citric acid monohydrate, trisodium citrate dihydrate, and sodium chloride.
11. The method of claim 10 , wherein the pharmaceutical composition comprises 0.25% w/v amisulpride.
12. The method of claim 10 , wherein the pharmaceutical composition comprises 0.25% w/v amisulpride, 0.935% w/v citric acid monohydrate, 1.632% w/v trisodium citrate dihydrate, and 0.18% w/v sodium chloride.
Assignments (5)
SECURITY INTEREST
Recorded Apr 27, 2026
From: LXO IRELAND DESIGNATED ACTIVITY COMPANY
To: KROLL TRUSTEE SERVICES LIMITED, AS SECURITY AGENT
Reel/Frame 074483/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 4, 2026
From: ACACIA PHARMA LIMITED; ACACIA PHARMA, INC.; EAGLE PHARMACEUTICALS, INC.
To: LXO IRELAND DESIGNATED ACTIVITY COMPANY; LXO US, INC.
Reel/Frame 073967/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 26, 2026
From: GILBERT, JULIAN CLIVE; GRISTWOOD, ROBERT WILLIAM; COOPER, NICOLA; FOX, GABRIEL
To: ACACIA PHARMA LIMITED
Reel/Frame 073910/0323 →
RELEASE OF SECURITY INTEREST
Recorded Apr 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ACACIA PHARMA LIMITED
Reel/Frame 070698/0351 →
SECURITY INTEREST
Recorded Oct 11, 2024
From: ACACIA PHARMA LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 068873/0911 →
Priority Claims (1)
GB 1004020
· Mar 11, 2010
· national
Continuity (11)
Continuation
PCTGB2011050472
· Mar 10, 2011
References Cited (74)
US 4294828A
· Thominet
· 1981
[cited by applicant]
US 6169094B1
· Perrault et al.
· 2001
[cited by applicant]
US 8686019B2
· Gilbert et al.
· 2014
[cited by applicant]
US 9084765B2
· Gilbert et al.
· 2015
[cited by applicant]
US 9119836B2
· Gilbert et al.
· 2015
[cited by applicant]
US 9545426B2
· Gilbert et al.
· 2017
[cited by applicant]
US 9889118B2
· Gilbert et al.
· 2018
[cited by applicant]
US 20070190145A1
· Venkatesh et al.
· 2007
[cited by applicant]
US 20080188537A1
· Azorin
· 2008
[cited by applicant]
US 20090175939A1
· Bosse et al.
· 2009
[cited by applicant]
US 20170087128A1
· Gilbert et al.
· 2017
[cited by applicant]
AU 2002361185A1
· 2003
[cited by applicant]
DE 102005013726A1
· 2006
[cited by applicant]
JP 2009524697A
· 2009
[cited by applicant]
WO 0003740A2
· 2000
[cited by applicant]
WO 2003053427A1
· 2003
[cited by applicant]
WO 2006106358A2
· 2006
[cited by applicant]
WO 2007067714A2
· 2007
[cited by applicant]
WO 2007090082A2
· 2007
[cited by applicant]
WO 2007093909A1
· 2007
[cited by applicant]
WO 2009126931A2
· 2009
[cited by applicant]
Yang, Evaluation on the Concomitant Use of Nervous System & Psychotherapeutic Drugs and Other Drugs, Evaluation and analysis of drug use in hospitals of China, 2008, vol. 8 No. 4, 246-249.
[cited by applicant]
Amisulpride, Barhemsys, Chinese Journal of Medicinal Chemistry, vol. 31, No. 2, p. 165, Feb. 2021.
[cited by applicant]
Amisupride 50mg Tablets—Summary of Product Characteristics (SmPC), https://www.medicines.org.uk/emc/product/548/smpc/print, accessed on Nov. 13, 2020, 7 pages.
[cited by applicant]
Candiotti, et al., Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Amisulpride as Treatment of Established Postoperative Nausea and Vomiting in Patients Who Have Had No Prior Prophylaxis, Ambulatory An…
[cited by applicant]
Chen and Ensor, “The Influence of Diphenhydramine.cndot.HC1 (Benadryl) On Apomorphine-Induced Emesis in Dogs”, Journal of Pharmacology and Experimental Therapeutics, 98:245-250 (1950).
[cited by applicant]
Chen et al., Efficacy and Safety of Amisulpride in Preventing Postoperative Nausea and Vomiting: A Meta-analysis, Herald of Medicine, vol. 38, No. 11, Nov. 2019, 1487-1493 (with English Abstract).
[cited by applicant]
Cook-Sather et al, “Cisapride Does Not Prevent Postoperative Vomiting in Children”, Anesth Analg, vol. 94, No. 1, 2002, pp. 50-54.
[cited by applicant]
De Mei, Getting specialized: presynaptic and postsynaptic dopamine D2 receptors, Curr. Opin. Pharmacol., 9(1), Feb. 2009, 53-58.
[cited by applicant]
Depoortere et al. “Apomorphine-Induced Emesis in Dogs: Differential Sensitivity to Established and Novel Dopamine D2/5-HT1A Antipsychotic Compounds.” Eur. J. Pharmcol. 597.1-3(2008):34-38.
[cited by applicant]
Dopaminergic receptors, New Pharmacology (New Yakuri-gaku) 3rd Edition, Japan, Nankodo, Nov. 25, 1996, p. 112-113.
[cited by applicant]
Elwood, et al., Emesis in dogs: a review, Journal of Small Animal Practice, vol. 51, Jan. 2010, 4-22.
[cited by applicant]
Gan et al., Intravenous Amisulpride for the Prevention of Postoperative Nausea and Vomiting, Two Concurrent, Randomized, Double-blind, Placebo-controlled Trials, Anesthesiology, vol. 125, No. 2, Feb. 2017, 268-275.
[cited by applicant]
Gan et al., Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting, Ambulatory Anesthesiology, vol. 105, No. 6, Dec. 2007, 1615-1628.
[cited by applicant]
Gardner et al., The broad spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040, Brit. J. Pharmacol., 1995, vol. 116, 3158-3163.
[cited by applicant]
Gatto, Clinical Efficacy and Safety of Levosulpiride and Domperidone in the Management of Chronic Functional Dyspepsia: A Double-Blind, Randomized Clinical Trial, Current Therapeutic Research, vol. 51, No. 5, May 1992, …
[cited by applicant]
Geodon 20mg Capsules, Summary of Product Characteristics, Pfizer Healthcare Ireland, http://www.medicines.ie/printfriendlydocument.aspx?documentid=6166&companyid=157, accessed on Feb. 24, 2014, 12 pages.
[cited by applicant]
Guideline for drug prevention and treatment of chemotherapy-induced nausea and vomiting, Chinese Journal of Hospital Pharmacy, https://kns.cnki.net/kcms/detail/42.1204.r.20220104.1444.006.html, ISSN 1001-5213, CN 42-120…
[cited by applicant]
Guslandi M: “Antiemetic properties of levo-sulpiride”, Minerva Medica, Edizioni Minerva Medica, Torino, IT, vol. 81, No. 12, Dec. 1, 1990 (Dec. 1, 1990), pp. 855-860.
[cited by applicant]
Guslandi, The Clinical Use of Levosulpiride, Current Therapeutic Research, vol. 53, No. 3, May 1993, 484-501.
[cited by applicant]
Habib, et al., Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis, A Randomized, Placebo-controlled Phase III Trial, Anesthesiology, vol. 130, No. 2, Feb. 2019, 203-…
[cited by applicant]
Henzi, et al., Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies, British Journal of Anaesthesia, 83(5), 761-771, 1999.
[cited by applicant]
Hesketh, “Chemotherapy—induced nausea and vomiting,” The New England Journal of Medicine, vol. 358, No. 23, Jun. 5, 2008, pp. 2482-2494.
[cited by applicant]
Hesketh, P.J., “Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice”, The Oncologist, 4:191-196 (1999).
[cited by applicant]
Hirokawa et al., “Synthesis and Structure-Affinity Relationships of Novel N-(1-Ethyl-4-methylhexahydro-1.4-diazepin-6-yl)pyridine-3-carboxamides with Potent Serotonin 5-HT3 and Dopamine 02 Receptor Antagonistic Activity…
[cited by applicant]
Horn et al., Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting, European Journal of Pharmacology, 722, 2014, 55-66.
[cited by applicant]
Jordan K et al: “Neue antiemetische Strategien—nicht nur in der Onkologie”, Der Internist; Organ Des Berufsverbandes Deutscher Internisten Organ Der Deutschen Gesellschaft Fur Innere Medizin, Springer, Berlin, De, vol. …
[cited by applicant]
Kranke et al., “Intravenous Buspirone for the Prevention of Postoperative Nausea and Vomiting”, Eur. J. Clin. PharmacoL 68: 1465-1472 (2012).
[cited by applicant]
Kranke et al., Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk, A Randomized, Double-blind, Placebo-controlled Trial, Anesthesiology, vol. 128, No. 6, Jun. 2018, 1099-1106.
[cited by applicant]
Lefebvre et al., “Gastric relaxation and vomiting by apomorphine, morphine and fentanyl in the conscious dog”, European Journal of Pharmacology, 1981, vol. 69, pp. 139-145.
[cited by applicant]
Ma, et al., Commonly Used Vomiting Animal Models, Chinese Journal of Experimental Traditional Medical Formulae, vol. 25, No. 13, Jul. 2019, 206-213 (with English Abstract).
[cited by applicant]
Magnani, M., “Amisulpride: Pharmacological and biochemical aspects”, Farmacia E Clinica, 33(3):91-97 (1994).
[cited by applicant]
Makita, K., Practical Anesthesia Series “Countermeasure to PONY and Anesthesia”, Anet. (quarterly journal), Maruishi Pharmaceutical, vol. 8, No. 2, pp. 18-24 (2004).
[cited by applicant]
Mccracken et al., “Guideline for the Management of Postoperative Nausea and Vomiting”, SOGC Clinical Practice Guideline, No. 209, pp. 600-607 (2008).
[cited by applicant]
Minami et al., “Role of serotonin in emesis,” Folia Pharmacal., pp. 233-242, vol. 108 (1996).
[cited by applicant]
Murakuni, “Mechanism of action of morphine in nausea/vomiting and countermeasures”, Palliative Medicine, vol. 3, No. 1: pp. 72-78 (2001).
[cited by applicant]
Pizzo et al., “Oral cisapride for the control of delayed vomiting following high-dose cisplatin”, Supportive Care in Cancer, vol. 7, No. 1, 1999, pp. 44-46.
[cited by applicant]
Porreca et al. “Nausea and Vomiting Side Effects with Opioid Analgesics During Treatment of Chronic Pain: Mechanisms, Implications, and Management Options.” Pain Med. 10.4(2009):654-662.
[cited by applicant]
Puech et al. “Pharmacological Classification of Benzamides.” Acta Psyhciatr. Scand. Suppl. 311(1984):139-143.
[cited by applicant]
Richards et al., Droperidol Analgesia for Opioid-Tolerant Patients, Pharmacology in Emergency Medicine, The Journal of Emergency Medicine, 2010, 1-8.
[cited by applicant]
Risperdal Tablets, Liquid & Quicklet, Summary of Product Characteristics, Janssen-Cilag Ltd, http://www.medicines.org.uk/emc/printfriendlydocument.aspx?documentid=12818, accessed Feb. 24, 2014, 19 pages.
[cited by applicant]
Risperidone 0.5 mg Film-coated Tablets, Summary of Product Characteristics (SmPC), https://www.medicines.org.uk/emc/product/5990/smpc/print, accessed on Nov. 16, 2020, 17 pages.
[cited by applicant]
Roila et al., “Prevention of chemotherapy-and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference”, Annals of Oncology, vol. 17, No. 1, Jan. 2006, pp. 20-28.
[cited by applicant]
Rowbottom, et al., An Overview of Radiation-Induced Nausea and Vomiting, Journal of Medical Imaging Radiation Sciences, 47, 2016, S29-S38.
[cited by applicant]
Spano: “Sulpiride and other benzamides”, Jan. 1, 1978 (Jan. 1, 1978) pp. 48-49.
[cited by applicant]
Sulpiride, Wikipedia: The Free Encyclopedia. Wikimedia Foundation, Inc., Jun. 6, 2009. Web. Jun. 25, 2009. http://web.archive.org/web/20090729132126/http://en.wikipedia.org/wiki/Sulpiride.
[cited by applicant]
Takei, D. et al., “Drug Therapy for Nausea and Vomiting”, J. Pharm. Palliat. Care Sci., pp. 111-117, vol. 2 (2009}. (with English Abstract).
[cited by applicant]
Tonini et al. J. Exp. Clin. Cancer Res., 2003, vol. 22, No. 1, pp. 17-22 (ABSTRACT attached).
[cited by applicant]
Torta et al. “Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies”, Support Care Cancer, No. 15, pp. 539-546, 2007.
[cited by applicant]
Wang, Clinical Application of Antipsychotic Medicine, Journal of Inner Mongolia University for Nationalities, vol. 23, No. 5, Sep. 2008, 588-591 (English Abstract included).
[cited by applicant]
Wynn, et al., The effects of different antiemetic agents on morphine-induced emesis in ferrets, European Journal of Pharmacology, 241, 1993, 47-54.
[cited by applicant]
Yan, The Study of Effects of Tiapride on Kindled Models, 2007, 54 pages (English Abstract included).
[cited by applicant]